Palvella Therapeutics (PVLA) Price & Analysis

Compare

674 Followers

PVLA Stock Chart & Stats

$78.63

-$0.34(-2.31%)

At close: Jan 08 4:00 PM EST

$78.63

-$0.34(-2.31%)

Day’s Range― - ―

52-Week Range$11.17 - $77.77

Previous CloseN/A

Volume11.83K

Average Volume (3M)196.25K

Market Cap

$830.14M

Enterprise Value$193.21M

Total Cash (Recent Filing)$70.43M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.02

Next Earnings

Nov 11, 2025

EPS Estimate

-0.84

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.86

Shares Outstanding11,059,665

10 Day Avg. Volume228,984

30 Day Avg. Volume196,255

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.43

Price to Sales (P/S)0.00

P/FCF Ratio-2.46

Enterprise Value/Market Cap0.23

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-12.81

Forecast

1Y Price Target

$113.78

Price Target Upside44.70% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market OpportunityWith no approved therapies, there is a significant unmet need in this patient population.

Platform ExpansionExpanding the QTORIN platform beyond Rapamycin to include a statin provides evidence of the breadth and scalability of the platform.

Regulatory AdvancementsThe program is expected to follow the same expedited, 505(b)(2) pathway as the QTORIN rapamycin programs, from IND to PoC in less than 2.5 years at low cost—moving rapidly into pivotals.

Bears Say

Disease RarityAngiokeratomas represent a rare, dermatological disease with no FDA approved agents.

Management ChallengesCVMs present unique management challenges compared with deep venous malformations in that these lesions often evade early detection, are difficult to access surgically, and current systemic therapies have limited effectiveness.

Palvella Therapeutics News

Palvella Therapeutics price target raised to $110 from $73 at Chardan

Chardan analyst Geulah Livshits raised the firm’s price target on Palvella Therapeutics (PVLA) to $110 from $73 and...

22h ago

PVLA

Palvella Therapeutics price target raised to $97 from $65 at TD Cowen

TD Cowen raised the firm’s price target on Palvella Therapeutics (PVLA) to $97 from $65 and keeps a...

2d ago

PVLA

Palvella Therapeutics price target raised to $200 from $120 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $120 and keeps an...

2d ago

PVLA

Palvella Therapeutics price target raised to $190 from $95 at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on Palvella Therapeutics (PVLA) to $190 from $95...

2d ago

PVLA

Palvella Therapeutics price target raised to $87 from $80 at Stifel

Stifel raised the firm’s price target on Palvella Therapeutics (PVLA) to $87 from $80 and keeps a Buy...

3d ago

PVLA

Palvella price target raised to $200 from $120 at Cantor Fitzgerald

Cantor Fitzgerald analyst Josh Schimmer raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $120...

3d ago

PVLA

Ligand price target raised to $250 from $190 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the firm’s price target on Ligand (LGND) to $250 from $190 and keeps...

5d ago

LGND

PTHS

Palvella received second year of funding under its FDA Office of OPD grant

Palvella Therapeutics (PVLA) announced it has received the second year of funding under its FDA Office of Orphan...

26d ago

PVLA

Palvella Therapeutics price target raised to $90 from $66 at Canaccord

Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $90 from $66 and keeps a Buy...

30d ago

PVLA

Buy Rating for Palvella Therapeutics: Innovative Approach and Strategic Development in Rare Dermatological Treatments

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Palvella Therapeutics, retaining the price target of...

2d ago

PVLA

Strategic Expansion of Palvella Therapeutics’ QTORIN Platform Targets Unmet Needs in Rare Skin Conditions

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Palvella Therapeutics, with...

3d ago

PVLA

Palvella Therapeutics Unveils QTORIN™ Pitavastatin for DSAP

An announcement from Palvella Therapeutics ( ($PVLA) ) is now available. On November 5, 2025, Palvella Therapeutics announced...

3d ago

PVLA

Palvella Therapeutics’ Phase 2 Study on PTX-022: A Potential Game-Changer for Cutaneous Venous Malformations

Palvella Therapeutics, Inc. (($PVLA)) announced an update on their ongoing clinical study. Palvella Therapeutics, Inc. is conducting a...

12d ago

PVLA

Palvella Therapeutics Advances Phase 3 Study on QTORIN Gel for Rare Disease

Palvella Therapeutics, Inc. (($PVLA)) announced an update on their ongoing clinical study. Palvella Therapeutics, Inc. is conducting a...

12d ago

PVLA

PVLA FAQ

What was Palvella Therapeutics’s price range in the past 12 months?

Palvella Therapeutics lowest stock price was $11.17 and its highest was $77.77 in the past 12 months.

What is Palvella Therapeutics’s market cap?

Palvella Therapeutics’s market cap is $830.14M.

When is Palvella Therapeutics’s upcoming earnings report date?

Palvella Therapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 3 days.

How were Palvella Therapeutics’s earnings last quarter?

Palvella Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.741 by -$0.119.

Is Palvella Therapeutics overvalued?

According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palvella Therapeutics pay dividends?

Palvella Therapeutics does not currently pay dividends.

What is Palvella Therapeutics’s EPS estimate?

Palvella Therapeutics’s EPS estimate is -0.84.

How many shares outstanding does Palvella Therapeutics have?

Palvella Therapeutics has 11,059,665 shares outstanding.

What happened to Palvella Therapeutics’s price movement after its last earnings report?

Palvella Therapeutics reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.741. Following the earnings report the stock price went up 3.271%.

Which hedge fund is a major shareholder of Palvella Therapeutics?

Currently, no hedge funds are holding shares in PVLA

Palvella Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

194.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Palvella Therapeutics

Palvella Therapeutics (PVLA) is a biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare, and genetic dermatological conditions. The company's core product pipeline includes treatments designed to address unmet medical needs in these specialized sectors, leveraging innovative drug delivery systems to enhance patient outcomes.

Palvella Therapeutics (PVLA) Earnings & Revenues

Historic Earnings Reports

PVLA Company Deck

PVLA Earnings Call

Q2 2025

0:00 / 0:00

PVLA Stock 12 Month Forecast

Average Price Target

$113.78

▲(44.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","106":"$106","201":"$201","58.5":"$58.5","153.5":"$153.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$113.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,58.5,106,153.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.84,89.08307692307693,98.32615384615386,107.56923076923077,116.8123076923077,126.05538461538463,135.29846153846154,144.54153846153847,153.7846153846154,163.02769230769232,172.27076923076925,181.51384615384615,190.7569230769231,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.84,82.45076923076924,85.06153846153846,87.6723076923077,90.28307692307692,92.89384615384616,95.50461538461539,98.11538461538461,100.72615384615385,103.33692307692309,105.94769230769231,108.55846153846154,111.16923076923078,{"y":113.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.84,79.08307692307693,78.32615384615384,77.56923076923077,76.8123076923077,76.05538461538461,75.29846153846154,74.54153846153847,73.78461538461539,73.0276923076923,72.27076923076923,71.51384615384616,70.75692307692307,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >